In a significant move within the pharmaceutical industry, a leading Indian drugmaker has expanded its diabetes care portfolio by acquiring a prominent insulin brand from Eli Lilly, a global healthcare company. This strategic acquisition, building upon an existing distribution partnership, aims to enhance access to essential insulin treatments for millions of diabetes patients across India.
Share Price Movement
The share price of Lupin Limited reached an intraday high of 1.35 percent to Rs. 2,342.65 per share on Tuesday, an increase from its previous close of Rs. 2,311.35 per share. The market capitalisation now stands at approximately Rs. 1,05,983 crore as of December 31, 2024.
Share Price Surge: Why?
Lupin has acquired Huminsulin from Eli Lilly in India to strengthen its diabetes treatment options. Lupin has already been selling Huminsulin, which is a type of human insulin, through agreements with Lilly India. Huminsulin is used to help manage blood sugar levels in people with type 1 and type 2 diabetes, benefiting both adults and children.
Financial Highlights
According to its recent filing, in the quarter ending September 2024, Lupin’s consolidated revenue from operations has increased by 12.58 percent YOY from Rs. 5,039 crore in Q2 FY24 to Rs. 5,673 crore in Q2 FY25 and increased by 1.30 percent QoQ from Rs. 5,600 crore in Q4 FY24.
The company’s consolidated net profit has increased by 72.92 percent, from Rs. 495 crore in Q2 FY24 to Rs. 859 crore in Q2 FY25. As compared to the last quarter of 2025, the company’s net profit has increased by 6.57 percent QoQ from Rs. 806 crore.
Market Outlook
The pharmaceutical industry is undergoing transformative changes post-pandemic, emphasising local supply security, affordability, and patient-centric approaches. Global medicine consumption is set to reach 3.8 trillion daily doses by 2028, with speciality drugs dominating over 40% of spending.
Growth drivers include oncology, immunology, and diabetes, fuelled by innovation and patent expirations. Challenges like pricing pressures, rising costs, and supply chain disruptions demand efficiency and digital innovation. Companies must adapt with agility to leverage opportunities in a complex, evolving global market.
Also read…..
Shareholding Pattern
As of the September 2024 shareholding pattern, Lupin Limited is primarily held by the promoters at 46.96 percent, foreign institutional investors hold 21.50 percent, and the public with 6.44 percent.
About Company
Lupin Limited, based in Mumbai, India, and founded in 1968 by Dr. Desh Bandhu Gupta, is a leading pharmaceutical company with over 21,000 employees. The company specialises in generic and branded drugs, biotech products, and APIs, operating in over 100 countries, including the U.S. and India.
Lupin focuses on cardiovascular, diabetes, paediatric, asthma, CNS disorders, and anti-tuberculosis medications. Through strategic acquisitions like Gavis Pharmaceuticals, Novel Laboratories, and Medisol in France, Lupin has expanded its global reach, with major operations in the U.S. and manufacturing facilities in India, Mexico, and Brazil, showcasing its dedication to innovation and addressing global health challenges.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
